文献速递胸部肿瘤

舒格利单抗联合铂类化疗对比安慰剂联合铂类化疗一线治疗转移性非小细胞肺癌(GEMSTONE-302):双盲随机3期试验4年结局

Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2025-06-13

GEMSTONE-302是一项在中国35家医院开展的双盲随机3期试验,479例初治IV期NSCLC患者按2:1随机接受舒格利单抗或安慰剂联合铂类化疗。4年事后分析显示,舒格利单抗组中位总生存25.2个月 vs 安慰剂组16.9个月(HR 0.68),4年总生存率32.1% vs 17.3%,安全性可控。

要点

  • 舒格利单抗组中位总生存25.2个月 vs 安慰剂组16.9个月(HR 0.68,95%CI 0.54-0.85)。
  • 4年总生存率舒格利单抗组32.1% vs 安慰剂组17.3%。
  • 最常见3-4级治疗相关不良事件为中性粒细胞计数降低(33% vs 33%)。

核心结论

  • 舒格利单抗联合化疗一线治疗无已知EGFR、ALK、ROS1或RET敏感基因组变异的NSCLC患者,较安慰剂联合化疗显示更优的长期总生存获益。

研究设计与样本

  • 随机、双盲、3期试验,在中国35家医院和学术研究中心开展。
  • 纳入18-75岁、初治、组织学或细胞学确诊的IV期NSCLC患者,不限PD-L1表达水平,ECOG体力状况评分0或1。
  • 479例患者按2:1随机分配至舒格利单抗组(n=320)或安慰剂组(n=159)。
  • 舒格利单抗1200 mg或安慰剂联合组织学特异性铂类化疗,最多4周期,随后维持治疗最多35周期。
  • 主要终点为意向治疗人群研究者评估的无进展生存期;本报告为事后4年疗效和安全性分析。

主要发现

  • 中位无进展生存期舒格利单抗组9.0个月(95%CI 7.4-10.9) vs 安慰剂组4.9个月(95%CI 4.8-5.2),HR 0.49(95%CI 0.39-0.60)。
  • 中位总生存期舒格利单抗组25.2个月(95%CI 20.1-30.2) vs 安慰剂组16.9个月(95%CI 12.8-20.7),HR 0.68(95%CI 0.54-0.85)。
  • 4年总生存率舒格利单抗组32.1%(95%CI 26.7-37.6) vs 安慰剂组17.3%(95%CI 11.1-24.7)。
  • 最常见3-4级治疗相关不良事件:中性粒细胞计数降低舒格利单抗组105例(33%) vs 安慰剂组52例(33%),白细胞计数降低48例(15%) vs 27例(17%),贫血44例(14%) vs 18例(11%),血小板计数降低35例(11%) vs 15例(9%)。
  • 治疗相关严重不良事件舒格利单抗组82例(26%) vs 安慰剂组31例(20%);自上次总生存期中分析以来未发生额外治疗相关死亡,未发现新的安全性信号。

临床怎么用

  • 作者认为,舒格利单抗联合铂类化疗可作为鳞状和非鳞状转移性NSCLC的标准一线治疗选择,同时保持可控的安全性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: GEMSTONE-302 was a phase 3 trial in patients with treatment-naive metastatic squamous or non-squamous non-small-cell lung cancer (NSCLC), showed significant improvement in progression-free survival and overall survival with sugemalimab, a PD-L1 inhibitor, plus chemotherapy versus placebo plus chemotherapy. We report the 4-year outcomes from this study. METHODS: This randomised, double-blind, phase 3 trial was conducted across 35 hospitals and academic research centres in China. Eligible patients were aged 18-75 years; had treatment-naive, histologically or cytologically confirmed stage IV NSCLC, irrespective of PD-L1 expression levels; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomised (2:1) by investigators using an interactive web response or voice response system via permuted blocks (block sizes of three or six, randomised within each stratum). Patients received histology-specific platinum-based chemotherapy combined with either sugemalimab (1200 mg; sugemalimab group) or placebo (placebo group) for up to four cycles, followed by for up to 35 cycles of maintenance therapy with sugemalimab alone for patients with squamous NSCLC and sugemalimab plus pemetrexed for patients with non-squamous NSCLC in the sugemalimab group, or placebo for patients with squamous NSCLC and placebo plus pemetrexed for patients with non-squamous NSCLC in the placebo group, administered intravenously. Treatment beyond 35 cycles was permitted at the investigator's discretion. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Here, we report post-hoc 4-year efficacy and safety outcomes from GEMSTONE-302. This study is registered with ClinicalTrials.gov (NCT03789604) and concluded on May 15, 2023, with all patients discontinued. FINDINGS: Between December 13, 2018, and May 15, 2020, 846 patients were assessed for eligibility. 479 patients were randomly assigned into the sugemalimab group (n=320) and placebo group (n=159). 254 (79%) patients were men and 66 (21%) were women in the sugemalimab group and 129 (81%) were men and 30 (19%) were women in the placebo group. All patients were Asian. As of the data cutoff on May 15, 2023, median follow-up durations were 43·5 months (IQR 41·2-46·9) in the sugemalimab group and 43·0 months (40·7-44·8) in the placebo group; median treatment durations were 7·2 months (4·2-18·8) with sugemalimab and 4·6 months (2·8-6·9) with placebo. Median progression-free survival was 9·0 months (95% CI 7·4-10·9) in the sugemalimab group versus 4·9 months (4·8-5·2) in the placebo group (hazard ratio [HR] 0·49 [95% CI 0·39-0·60]). Median overall survival was 25·2 months (20·1-30·2) in the sugemalimab group versus 16·9 months (12·8-20·7) in the placebo group (HR 0·68 [0·54-0·85]). The 4-year overall survival rates were 32·1% (95% CI 26·7-37·6) in the sugemalimab group versus 17·3% (11·1-24·7) in the placebo group. The most common grade 3-4 treatment related adverse events were decreased neutrophil count (105 [33%] with sugemalimab vs 52 [33%] with placebo), decreased white blood cell count (48 [15%] vs 27 [17%]), anaemia (44 [14%] vs 18 [11%]), and decreased platelet count (35 [11%] vs 15 [9%]). Treatment-related serious adverse events occurred in 82 (26%) patients with sugemalimab and 31 (20%) with placebo. No additional treatment-related deaths occurred since the previous overall survival interim analysis. No new safety signals were identified. INTERPRETATION: Sugemalimab with chemotherapy showed a superior long-term overall survival benefit compared with placebo with chemotherapy, as a first-line treatment for patients with NSCLC with no known sensitising EGFR, ALK, ROS1, or RET genomic alterations. These results underscore the efficacy of sugemalimab plus platinum-based chemotherapy as a standard first-line treatment option for both squamous and non-squamous metastatic NSCLC while maintaining a manageable safety profile. FUNDING: CStone Pharmaceuticals. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Zhou C, Wang Z, Sun M, et al. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial. Lancet Oncol. 2025. PMID: 40523368. doi:10.1016/S1470-2045(25)00198-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。